DUBLIN--(BUSINESS WIRE)--Mallinckrodt plc (NYSE: MNK) announced today that it has selected winners in the annual Science Week competition. On Friday, 31st January, the company will welcome Minister Joan Burton to its Damastown facility to award a total of €4,000 worth of scientific equipment to the top three entries. The competition, which this year has the theme “What Does Chemistry Mean to Me in My Everyday Life?”, was launched in November, 2013, in conjunction with Pharmachemical Ireland and was open to first-year students in secondary schools in the Dublin 15 / County Meath area.
Representing Mallinckrodt and presenting the awards will be Dr. David Keenan, recently named Vice President, Global External Manufacturing and Managing Director of Mallinckrodt Pharmaceuticals – Ireland.
Minister Burton said: “I’m delighted to join Mallinckrodt in presenting these awards – it’s refreshing to see an interest in science from children at such a young age and gratifying to see a company like Mallinckrodt supporting science programs in our schools. Over the years Ireland has established itself as a hub for industries in the areas of science, technology and pharmaceuticals and the natural interest in these areas from our younger generation inspires hope that this will continue.”
Dr. Keenan said, “I am delighted that we were able to launch these awards as part of a larger 20th anniversary celebration of our manufacturing presence in Ireland, and gratified by the support and interest shown by Minister Burton. These are exciting times at Mallinckrodt as we position ourselves to be a top quartile speciality pharmaceutical company. I am pleased to take on the leadership role of our Global External Manufacturing efforts here in Ireland, which is an indication of the strategic value we see in our presence here. As Mallinckrodt grows, our external manufacturing strategy will become increasingly important as we identify and leverage strategic partners and technologies to enhance value.”
In Damastown, Mallinckrodt employs more than 100 individuals in its Principal Executive Office and Manufacturing Facility. The 82,000-square-foot, state-of-the-art facility has produced ioversol, a bulk active pharmaceutical ingredient for contrast media, since 1993.
Mallinckrodt was formed in January 2013, to hold the pharmaceuticals business of its former parent, and was spun off from its parent on June 28, 2013.
Mallinckrodt is a global specialty pharmaceutical business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company’s Specialty Pharmaceuticals segment includes branded and generic drugs and active pharmaceutical ingredients, and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt has approximately 5,500 employees worldwide and commercial presence in roughly 70 countries. The company’s fiscal 2013 revenue totaled $2.2 billion. To learn more about Mallinckrodt, visit www.mallinckrodt.com.